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Abstract The rapid clinical embrace of next generation
multigene cancer predisposition panels has resulted in
discovery of DNA variants in genes for which very limited
data on penetrance has been published. Evidence for
increased risks associated with these genes is often
expressed in odds ratios and studies often were conducted
on a priori high risk cohorts, i.e. those with young onset
disease and/or positive family histories. Despite these
limitations, one can estimate cumulative risks, which may
be useful for health care providers who are counselling
individuals on their results. We present cumulative risks for
several under-studied genes and provide generic informa-
tion that can be extrapolated to data still emerging.
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Introduction
For clinicians providing cancer risk assessment for carriers
of rare variants in genes for which there is very limited
information on risk, one problem is the non-uniform
manner in which risk estimates are presented. Cumulative
lifetime risk, the most familiar and intuitive concept, is
typically used in clinical guidelines such as the US
Preventive Services Task Force recommendation to offer
magnetic resonance imaging screening to women whose
lifetime risk of breast cancer exceeds 20–25 %. Therefore,
when publications present odds ratios (ORs), relative risks,
or standardized incidence ratios, it is necessary to convert
those estimates.
Methods
Following a literature review, we compiled examples of
published risk estimates for pathogenic variants now being
detected by some of the new breast cancer gene panels
and have converted these so the risks for carriers can be
expressed in terms of cumulative risks (Table 1). To cal-
culate the cumulative risks, we used USA population
incidences compiled by the International Agency for
Research on Cancer and a formula relating a hazard ratio
to the age-specific cumulative risks. In detail, the age-
specific cumulative risk to age T years for carriers was
calculated as one minus the exponential of minus the
cumulative incidence to age T years, where the cumula-
tive incidence to age T years is the sum, as S ranges over
all ages between 0 and T years, of the population inci-
dence at age S years times the hazard ratio at age S years.
We assumed that the hazard ratios (definition: the ratio of
age-specific breast cancer incidence in carriers to that in
non-carriers) for the genetic variants are approximately
equal to their reported ORs (definition: the ratio of the
odds of breast cancer for carriers divided by that of non-
carriers), standardized incidence ratios (definition: ratio of
the observed rate of breast cancer to the age-adjusted
expected rate in the general population) or relative risks
(definition: the ratio of the risk of breast cancer in gene
carriers compared to the risk among those who are not
gene carriers).
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Results
Table 1 shows the published risk estimates for specific
genes and/or variants within genes. Using the strategy
described, this risk is converted to a cumulative risk to age
70 years for carriers living in the USA and other countries
with similar population incidences.
Discussion
Establishing penetrance is a difficult proposition, even for
extensively studied genes, like BRCA1 and BRCA2, in
which no two studies have ever yielded the same results.
Discrepancies are attributable to differences between pop-
ulations and to methodology. The range of penetrance
generally cited for the BRCA genes drives the clinical
recommendations for surveillance and prevention, and
provides a yardstick by which other genes can be compared
and contrasted. Conducting comparisons is very difficult
when the only published literature does not provide
cumulative risks/penetrance for these new genes. In this
paper, we sought to demonstrate one way to address this
gap.
Some cautions are warranted in accepting the risk
estimates provided in Table 1. Some of the published ORs
were estimated using cases selected for a family history,
so the corresponding ORs are only appropriate for women
with comparable family histories, but the published ORs
from studies unselected for family history are appropriate
for all carriers in general in the population studied. In this
case, the risk for an individual carrier is the product of her
risk due to the variant and her risk due to any family
history that she has. Note that, unlike high-risk mutations,
variants associated with a moderately increased risk
explain only a small portion of the cancer family history
of the carriers. Therefore, for carriers with a family his-
tory, their cumulative risk will depend on the increased
risks associated with both their cancer family history and
the variant itself [1]. For example, if a carrier of a variant
associated with an increased OR of cancer also has a
family history sufficient to triple her risk, her cumulative
risk will be about that of a woman with a 3 9 OR
increased risk.
In Fig. 1, we have plotted age-specific cumulative risks
for breast cancer corresponding to various hypothetical
hazard ratios. This generic plot can therefore be used to
estimate a carrier’s overall risk including cancer family
history and other known risk factors. Figure 1 can also be
used to gauge the degree of uncertainty in the overall
cumulative risk estimate from the uncertainty (as expressed
in confidence intervals) in the risk estimates.
Additional caution is warranted in use of these esti-
mates, because: validation studies have not been published
for most of these variants so the published ORs might be
subject to publication bias. The risks shown in Table 1 do
not reflect all known papers on the subject and new papers
are being published rapidly now; risk estimates might be
population-specific; and risk estimates have come from a
mixture of studies, some of which did not select cases on
the basis of family history and some that did. Also, in the
absence of a precise formula converting ORs to cumulative
risks, we have had to assume that reported ORs are close
to, if not identical to, the hazard ratios. We have also
assumed that the hazard ratio is constant with age, which is
unknown for these variants. For high-risk variants, such as
mutations in BRCA1, this is not true as the population of
higher risk carriers is depleted across the decades by death
from breast and ovarian cancers. For less lethal variants,
however, this will not be a major issue. We also assumed
that the incidences for non-carriers are the same as the
population incidence; this is likely true given these variants
are rare.
Risk estimates are but one factor that needs to be inte-
grated with other complex issues in individualizing medi-
cal management. We hope that the estimates and
confidence intervals in Table 1, and the cumulative risks in
Fig. 1, will be useful to clinicians given that cancer family
history and other risk factors are appropriately taken into
account.



































Fig. 1 Cumulative risks (CRs) for carriers of variants with various
hazard ratios (HRs), for carriers living in the USA and other countries
with similar population incidences. This figure provides a general
guidance for clinicians considering how risks of genes, based on very
limited data yet, compare with genes with more established manage-
ment strategies
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